Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux
Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux
复制标题
DOI：
10.1002/ajh.25632
复制
发表时间：
2019-12-01
影响因子：
12.8
通讯作者：
Godeau, Bertrand
中科院分区：
文献类型：
--
作者：
Deshayes, Samuel;Khellaf, Mehdi;Godeau, Bertrand
利妥昔单抗是成人免疫性血小板减少症（ITP）的二线选择，但仅基于汇总的回顾性数据，估计5年应答率约为20%，并且没有研究关注长期安全性。我们对248例接受利妥昔单抗治疗的ITP成人患者进行了一项前瞻性多中心登记研究，随访5年，以评估其长期安全性和有效性。中位随访时间为68.4 [53.7-78.5]个月。严重感染的发生率仅为2/100患者-年。严重的低丙种球蛋白血症（
Rituximab is a second-line option in adults with immune thrombocytopenia (ITP), but the estimated 5-year response rate, only based on pooled retrospective data, is about 20%, and no studies have focused on long-term safety. We conducted a prospective multicenter registry of 248 adults with ITP treated with rituximab with 5 years of follow-up to assess its long-term safety and efficacy. The median follow-up was 68.4 [53.7-78.5] months. The incidence of severe infections was only 2/100 patient-years. Profound hypogammaglobulinemia (